title: Case series: toxicity from 25B-NBOMe--a cluster of N-bomb cases.
abstract: Background A new class of hallucinogens called NBOMes has emerged. This class includes analogues 25I-NBOMe, 25C-NBOMe and 25B-NBOMe. Case reports and judicial seizures indicate that 25I-NBOMe and 25C-NBOMe are more prevalently abused. There have been a few confirmed reports of 25B-NBOMe use or toxicity. Report Observational case series. This report describes a series of 10 patients who suffered adverse effects from 25B-NBOMe. Hallucinations and violent agitation predominate along with serotonergic/stimulant signs such as mydriasis, tachycardia, hypertension and hyperthermia. The majority (7/10) required sedation with benzodiazepines. Analytical method 25B-NBOMe concentrations in plasma and urine were quantified in all patients using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method. Peak plasma levels were measured between 0.7-10.1 ng/ml. Discussion The NBOMes are desired by users because of their hallucinogenic and stimulant effects. They are often sold as LSD or synthetic LSD. Reported cases of 25B- NBOMe toxicity are reviewed and compared to our series. Seizures and one pharmacological death have been described but neither were observed in our series. Based on our experience with cases of mild to moderate toxicity, we suggest that management should be supportive and focused on preventing further (self) harm. High doses of benzodiazepines may be required to control agitation. Patients who develop significant hyperthermia need to be actively managed. Conclusions Effects from 25B-NBOMe in our series were similar to previous individual case reports. The clinical features were also similar to effects from other analogues in the class (25I-NBOMe, 25C-NBOMe). Violent agitation frequently present along with signs of serotonergic stimulation. Hyperthermia, rhabdomyolysis and kidney injury were also observed.
authors.affiliation: a Emergency Physician, Christchurch Hospital , Christchurch , New Zealand ;
authors.forename: Paul
authors.initials: P
authors.lastname: Gee
authors.affiliation: b Toxicologist National Poisons Centre, University of Otago , Dunedin , New Zealand ;
authors.forename: Leo J
authors.initials: LJ
authors.lastname: Schep
authors.affiliation: c Scientific Officer, Toxicology, Specialist Cluster, Canterbury Health Laboratories , Christchurch , New Zealand ;
authors.forename: Berit P
authors.initials: BP
authors.lastname: Jensen
authors.affiliation: d Toxicology Section Head, Specialist Cluster, Canterbury Health Laboratories , Christchurch , New Zealand ;
authors.forename: Grant
authors.initials: G
authors.lastname: Moore
authors.affiliation: e Emergency Physician, Christchurch Hospital , Christchurch , New Zealand.
authors.forename: Stuart
authors.initials: S
authors.lastname: Barrington
mesh_terms: D000328:Adult; D000840:Anisoles / Q000633:toxicity*; D001569:Benzodiazepines / Q000633:toxicity; D054042:Bombs; D002853:Chromatography, Liquid; D016000:Cluster Analysis; D004118:Dimethoxyphenylethylamine / Q000031:analogs & derivatives / Q000633:toxicity; D005260:Female; D006212:Hallucinations / Q000139:chemically induced / Q000473:pathology; D006213:Hallucinogens / Q000633:toxicity; D006801:Humans; D008297:Male; D010627:Phenethylamines / Q000633:toxicity*; D053719:Tandem Mass Spectrometry; D055815:Young Adult
chemical_list: D000840:Anisoles; D004118:Dimethoxyphenylethylamine; D006213:Hallucinogens; D010627:Phenethylamines; D001569:Benzodiazepines; C554181:2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; C000595926:2-(4-bromo-2,5-dimethoxyphenyl)-N-((2-methoxyphenyl)methyl)ethanamine
keywords: 25B-NBOMe; N-bomb; NBOMe; novel psychoactive substances; substituted phenylethylamines